Opinion|Videos|August 28, 2024
Comparing Treatment Options: Luspatercept vs. Erythropoiesis-Stimulating Agents (ESAs)
Experts discuss factors influencing the choice between luspatercept and erythropoiesis-stimulating agents (ESAs) for initial anemia treatment, considerations for transitioning patients from ESAs to luspatercept, optimal timing for such transitions, and the clinical benefits of luspatercept dose titration as evidenced by real-world data presented at EHA 2024.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- When it comes to initial anemia treatment beyond transfusions, there are different options available including luspatercept and erythropoiesis-stimulating agents (ESAs).
- What factors would you consider when deciding between these therapies for a particular patient?
- For patients already on ESAs, what would prompt you to consider transitioning them to luspatercept therapy?
- How do you determine the appropriate timing for such a switch?
- Please discuss the clinical benefit of luspatercept dose titration from the RWE data presented at EHA 2024.
Advertisement
Related to this article
Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.
The FDA granted fast track designation to SBE303, Samsung Bioepis’ investigational Nectin-4–targeting ADC, for advanced urothelial cancer following enfortumab vedotin.
The antibody-drug conjugate sofetabart mipitecan showed efficacy and safety, leading to selection of a phase 3 dose for the FRAmework-01 trial.
FDA grants orphan drug designation to onvansertib for relapsed or refractory CMML, boosting development of the PLK1 inhibitor after early signals of activity.
Findings highlight the need for individualized monitoring after discharge, despite low rates of severe toxicities.
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
The guidelines incorporate cosibelimab for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial.
New analysis reveals major gaps in US TNBC trial access, leaving rural and minority communities with fewer treatment options and research opportunities.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5